Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cocrystal Pharma, Inc. (Cocrystal or the Company) (NASDAQ:COCP) formerly known as BioZone Pharmaceuticals, Inc. (BioZone) of the November 19, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Cocrystal stock or options between September 23, 2013 and September 7, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/COCP. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].
The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Cocrystal and/or BioZone securities between September 23, 2013 and September 7, 2018 (the Class Period). The case, Pepe v. Cocrystal Pharma, Inc. f/k/a BioZone Pharmaceuticals, Inc. et al, No. 18-cv-14091 was filed on September 20, 2018 and has been assigned to Judge Kevin McNulty.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) the company and certain of its officers were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price; (2) this illicit scheme would result in governmental scrutiny, including from the U.S. Securities and Exchange Commission (SEC); (3) the Company failed to abide by SEC disclosure regulations; and (4) as a result, the Companys statements about Cocrystal’s business, operations and prospects were materially false and misleading.
Specifically, on September 7, 2018, the SEC filed a lawsuit against Phillip Frost, one of the Companys directors and shareholders, and others, alleging violations of federal securities laws. According to the SECs complaint, Phillip Frost allegedly participated in at least two unlawful pump-and-dump schemes involving various microcap companies.
After the lawsuit was announced, Cocrystals share price fell from $3.74 per share on September 6, 2018, to a closing price of $3.16 on September 11, 2018a $0.58 or a 15.51% drop.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Cocrystals conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
York, NY 10017
Attn: Richard Gonnello, Esq.
(877) 247-4292 or (212) 983-9330